Baxalta Races Full Steam Ahead Into 2016 With Hematology At The Fore
This article was originally published in Scrip
Baxalta Inc. is "energized and optimistic" for the New Year and expects to continue building up a strong portfolio and research pipeline on the back of a successful first six months as an independent new business.
You may also be interested in...
Although noises are still being made in Japan concerning the benefits of Shire's merger with Takeda, the former is going about the business of getting marketing green lights with the latest being for its inherited bleeding disorder treatment Veyvondi in Europe.
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.